Sun Pharmaceutical Industries Ltd.'s net profit declined in the first quarter of fiscal year 2026, as the bottom-line was dragged by a one-time exceptional loss of Rs 818 crore.
India's largest drugmaker's consolidated net profit fell nearly 20% year-on-year to Rs 2,154 crore in the June quarter, according to an exchange filing on Thursday. That compares with the Rs 3,042-crore consensus estimate of analysts tracked by Bloomberg.
Sun Pharma Q1 FY26 Results Highlights (Consolidated, YoY)
Revenue up 9.5% at Rs 13,851 crore vs Rs 12,653 crore (Bloomberg Estimate: Rs 13,699 crore)
Ebitda up 11.3% at Rs 4,073 crore versus Rs 3,658 crore (Bloomberg Estimate: Rs 3,835 crore)
Margin at 29.4% versus 28.9% (Bloomberg Estimate: 28%)
Net profit down 19.6% at Rs 2,279 crore versus Rs 2,836 crore (Bloomberg Estimate: Rs 3,042 crore)
India formulation sales at Rs 4721 crore, up 13.9%.
US formulation sales at US$ 473 million, up 1.4%.
Global innovative medicines sales at $ 311 million, up 16.9%.
Emerging markets formulation sales at $ 298 million, up 5.1%.
Rest of world formulation sales at $ 219 million, up 15.5%.
R&D investments stood at Rs. 902.9 crore or 6.5% of sales.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
